+86-21-58356573
LANGUAGE

Preclinical development of a bispecific antibody-trap selectively targeting CD47 and CD20 for the treatment of B cell lineage cancer. Tian et al, AACR, 2019.

       POSTER: Preclinical development of a bispecific antibody-trap selectively targeting CD47 and CD20 for the treatment of B cell lineage cancer. Tian et al, AACR, 2019.